Literature DB >> 30630987

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Adi J Klil-Drori1,2, Hui Yin1, Laurent Azoulay1,2,3, Michaël Harnois4, Michel-Olivier Gratton4, Lambert Busque4, Sarit E Assouline5,3,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30630987      PMCID： PMC6601075          DOI： 10.3324/haematol.2018.211235

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.

Authors:  Lina Eliasson; Sarah Clifford; Nick Barber; David Marin
Journal:  Leuk Res       Date:  2010-11-20       Impact factor: 3.156

Review 2.  Generic oncology drugs: are they all safe?

Authors:  Y Tony Yang; Sumimasa Nagai; Brian K Chen; Zaina P Qureshi; Akida A Lebby; Samuel Kessler; Peter Georgantopoulos; Dennis W Raisch; Oliver Sartor; Terhi Hermanson; Robert C Kane; William J Hrushesky; Joshua J Riente; LeAnn B Norris; Laura R Bobolts; James O Armitage; Charles L Bennett
Journal:  Lancet Oncol       Date:  2016-11       Impact factor: 41.316

3.  Bias from historical control groups used in orthodontic research: a meta-epidemiological study.

Authors:  Spyridon N Papageorgiou; Vasiliki Koretsi; Andreas Jäger
Journal:  Eur J Orthod       Date:  2016-04-29       Impact factor: 3.075

4.  The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.

Authors:  Erna Islamagic; Azra Hasic; Sabira Kurtovic; Emina Suljovic Hadzimesic; Lejla Mehinovic; Mirza Kozaric; Amina Kurtovic-Kozaric
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-02-16

5.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

Review 6.  Medication compliance and persistence: terminology and definitions.

Authors:  Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

7.  Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.

Authors:  Domingo Saavedra; Fabiola Vizcarra
Journal:  Leuk Lymphoma       Date:  2014-06-17

8.  Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.

Authors:  Alaa Fadhil Alwan; Bassam F Matti; Aladdin S Naji; Abdulsalam H Muhammed; Manal A Abdulsahib
Journal:  Leuk Lymphoma       Date:  2014-04-22

9.  Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.

Authors:  J Geissler; G Sharf; J Cugurovic; R Padua; Š Narbutas; M Remic; V Venkatesh
Journal:  Leukemia       Date:  2016-08-03       Impact factor: 11.528

10.  Outcome of Frontline Treatment with "Generic" Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study.

Authors:  B Entasoltan; M A Bekadja; H Touhami; N Mehalhal; Z Zouaoui; N Mesli; M Talbi; A Bachiri; M Michallet
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-10-25       Impact factor: 2.576
View more
  2 in total

1.  The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293).

Authors:  Ahmet Emre Eskazan; Teoman Soysal
Journal:  Haematologica       Date:  2019-07       Impact factor: 9.941

2.  Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.

Authors:  Maria Gemelli; Elena Maria Elli; Chiara Elena; Alessandra Iurlo; Tamara Intermesoli; Margherita Maffioli; Ester Pungolino; Maria Cristina Carraro; Mariella D'Adda; Francesca Lunghi; Michela Anghileri; Nicola Polverelli; Marianna Rossi; Mattia Bacciocchi; Elisa Bono; Cristina Bucelli; Francesco Passamonti; Laura Antolini; Carlo Gambacorti-Passerini
Journal:  Blood Res       Date:  2020-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.